These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17342503)

  • 1. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium.
    Sun Y; Jain A; Moshfeghi DM
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1387-8. PubMed ID: 17342503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.
    He YG; Wang H; Zhao B; Lee J; Bahl D; McCluskey J
    Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1519-21. PubMed ID: 20379736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis.
    Vianna RN; Squeri G; Turquetti R; Brasil OF; Burnier MN
    Can J Ophthalmol; 2008 Aug; 43(4):492-3. PubMed ID: 18711476
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children.
    Kaul S; Uparkar M; Mody K; Walinjkar J; Kothari M; Natarajan S
    Indian J Ophthalmol; 2010; 58(1):76-8. PubMed ID: 20029154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Coats disease with bevacizumab in 2 patients.
    Venkatesh P; Mandal S; Garg S
    Can J Ophthalmol; 2008 Apr; 43(2):245-6. PubMed ID: 18347637
    [No Abstract]   [Full Text] [Related]  

  • 6. Juxtafoveal telangiectasias.
    Querques G; Delle Noci N
    Ophthalmology; 2008 Sep; 115(9):1636; author reply 1636. PubMed ID: 18762079
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of intravitreal bevacizumab in the treatment of Coats disease in children.
    Lin CJ; Hwang JF; Chen YT; Chen SN
    Retina; 2010 Apr; 30(4):617-22. PubMed ID: 19996822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Holz FG; Scholl HP
    Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease.
    Cakir M; Cekiç O; Yilmaz OF
    J AAPOS; 2008 Jun; 12(3):309-11. PubMed ID: 18589387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreous ranibizumab as treatment for macular telangiectasia type 2.
    Lira RP; Silva VB; Cavalcanti TM; de Souza AC; Pinto AP
    Arch Ophthalmol; 2010 Aug; 128(8):1075-8. PubMed ID: 20697014
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis.
    Windisch R; Kozousek V
    Can J Ophthalmol; 2008 Aug; 43(4):489-90. PubMed ID: 18711474
    [No Abstract]   [Full Text] [Related]  

  • 12. Expounding newer vistas in VEGF.
    Natarajan S
    Indian J Ophthalmol; 2013; 61(1):1-2. PubMed ID: 23275212
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.
    Ramasubramanian A; Shields CL
    Br J Ophthalmol; 2012 Mar; 96(3):356-9. PubMed ID: 21653215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review.
    Mahmood S; Kumar N; Lenfestey PM; Murjaneh S; Heimann H; Harding SP
    Eye (Lond); 2009 Mar; 23(3):530-5. PubMed ID: 18425070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRANSCLERAL DRAINAGE OF SUBRETINAL FLUID, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, AND WIDE-FIELD IMAGING-GUIDED LASER IN COATS EXUDATIVE RETINAL DETACHMENT.
    Stanga PE; Jaberansari H; Bindra MS; Gil-Martinez M; Biswas S
    Retina; 2016 Jan; 36(1):156-62. PubMed ID: 26355946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coats' disease: treatment with intravitreal bevacizumab and laser photocoagulation.
    Stergiou PK; Symeonidis C; Dimitrakos SA
    Acta Ophthalmol; 2009 Sep; 87(6):687-8. PubMed ID: 18976310
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The article by Kovach and Rosenfeld.
    Charbel Issa P; Holz FG; Scholl HP
    Retina; 2009 May; 29(5):717; author reply 717-8. PubMed ID: 19430284
    [No Abstract]   [Full Text] [Related]  

  • 19. Vascular endothelial growth factor in Coats' disease.
    Zhao Q; Peng XY; Chen FH; Zhang YP; Wang L; You QS; Jonas JB
    Acta Ophthalmol; 2014 May; 92(3):e225-8. PubMed ID: 23764089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
    Nuzzi R; Tridico F
    Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.